1

MEDICAL PUBLICATION
CONFERENCES AND SEMINARS
MARKETING RESEARCH

  • Immunoprevention of contact children from focies of chemoresistant tuberculosis infection with BIVEL immunomodulator (BI-V)
en To content Full text of article

Immunoprevention of contact children from focies of chemoresistant tuberculosis infection with BIVEL immunomodulator (BI-V)

Modern Pediatrics. Ukraine. (2024). 7(143): 18-25. doi: 10.15574/SP.2024.7(143).1825
Sakhelashvili M. I.1, Piskur Z. I.1, Kostyk O. P.1, Sakhelashvili-Bil O. I.1, Starichek G. V.2, Shvaienko N. P.2, Tymchak E. V.2, Kashkadamova S. M.2, Stadovych O. I.2
1Danylo Halytsky Lviv National Medical University, Ukraine
2Lviv Regional Center of Medical and Social Expertise, Ukraine

For citation: Sakhelashvili MI, Piskur ZI, Kostyk OP, Sakhelashvili-Bil OI, Starichek GV, Shvaienko NP et al. (2024). Immunoprevention of contact children from focies of chemoresistant tuberculosis infection with BIVEL immunomodulator (BI-V). Modern Pediatrics. Ukraine. 7(143): 18-25. doi: 10.15574/SP.2024.7(143).1825.
Article received: Jul 16, 2024. Accepted for publication: Nov 12, 2024.

Aim – to study the feasibility of using the natural immunomodulator BIVEL (BI-V) as a non-specific immunoprevention of tuberculosis (TB) among contact children from focies of multidrug-resistant tuberculosis infection (FsMDR-TBI) on the basis of clinical and immunological studies.
Materials and methods. The object of study: 120 contacted from FsMDR-TBI (75 children and 45 adolescents). The Group 1 – 95 children/adolescents who did not receive BI-V and the Group 2 – 25 patients who received BI-V. The state of phagocytic reactivity of immunity; cellular and humoral immunity; interleukins and specific immunity were determined. Statistical analysis of the obtained results was performed based on a software package Excel.
Results. In infected children/adolescents with FsMDR-TBI, insignificant functional disorders of the cellular response were revealed (decrease by 1.3 times IRI CD3+CD4+/CD3+CD8+), a shift in the balance in the regulatory system towards pro-inflammatory cytokines (increase by 2.0 times TNF-α/IL-10). The existing deviations in the regulatory and cellular response systems disappeared after the completion of the autumn-spring BI-V course. Preventive administration of immunomodulator BI-V to infected children/adolescents with FsMDR-TBI reduced the frequency of acute respiratory viral infections and exacerbations of bronchopulmonary diseases by 2.0 times, the development of latent tuberculosis infection into an active process by 2.6 times. Among children of the Group 2 – 8% of people fell ill with various forms of primary pulmonary TB, among children of the Group 1 – 22.1%. In both groups, the maximum level of TB occurred in the first two years of observation.
Conclusions. The introduction of the algorithm of preventive measures with appointment of BI-V confirmed feasibility of using this immunomodulator for contact children/adolescents with FsMDR-TBI.
The study was carried out in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Local Ethical Committee of the participating institution. The informed consent of patient was obtained for conducting the studies.
No conflict of interests was declared by the authors.
Keywords: immunoprevention, contact children and adolescents, focies of multidrug-resistant tuberculosis.

REFERENCES

1. Barbova AI. (2016). Suchasni pidkhody do diahnostyky multyrezystentnoho tuberkulozu. Ukr. pulmonol. zhurnal. 2: 29-32. https://doi.org/10.1145/2911172.2911184

2. Belohortseva OY. (1998). Ymmunolohycheskaia y ymmunohenetycheskaia kharakterystyka detei s razlychnыmy formamy tuberkuleza. Ukr. pulmonol. zhurn. 1: 62-64.

3. Bilohortseva OI. (2008). Imunoprofilaktyka tuberkulozu u ditei: problemy i perspektyvy. Ukr. pulmonol. zhurn. 3; dodatok: 29-30.

4. Bilohortseva OI, Sukhanova LA, Shekhter IIe ta in. (2019). Rozspovsiudzhenist multyrezystentnoho tuberkulozu v Ukraini v konteksti zahalnoi zakhvoriuvanosti na tuberkuloz. Ukr. pulmonoloh. zhurn. 1; dodatok: 15-20.

5. Daly RM, Gagnon ZX, Lu et al. (2012). Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population-based study. Clinical Endocrinology (Oxf.). 77: 26-35. https://doi.org/10.1111/j.1365-2265.2011.04320.x; PMid:22168576

6. Dotsenko YaI, Bilohortseva OI. (2016). Hrupa ryzyku zakhvoriuvannia na tuberkuloz u ditei z latentnoiu tuberkuloznoiu infektsiieiu. Medychnyi forum. 7: 61-63.

7. Fares A. (2011). Seasonality of tuberculosis. J. Global Infectious Diseases. 3: 46-55. https://doi.org/10.4103/0974-777X.77296; PMid:21572609 PMCid:PMC3068579

8. Feshchenko YuI, Melnyk VM, Turchenko LV. (2016). Pohliad na problemu borotby z tuberkulozom v Ukraini. Ukr. pulmonoloh. zhurn. 3: 5-10.

9. Feshchenko YuY, Rekalova AM. (2016). Osobennosty sovremennoi ymmunomodulyruiushchei terapyy. Astma ta alerhiia. 2: 6-11.

10. MacLachlan JH, Lavender CJ, Cowie BC. (2012). Effect of Latitude on Seasonality of Tuberculosis, Australia, 2002-2011. Emerging Infectious Disease. 18: 1879-1881. https://doi.org/10.3201/eid1811.120456; PMid:23092594 PMCid:PMC3559156

11. Melnyk VM, Matusevych VH, Novozhylova IO, Veselovskyi LV. (2020). Multyrezystentnyi tuberkuloz lehen: sytuatsiia v Ukraini. Infusion & Chemotherapy. 1: 66-67. doi: 10.32902/2663-0338-2020-1-66-67.

12. MOZ Ukrainy. (2023). Standarty medychnoi dopomohy «Tuberkuloz». Nakaz MOZ Ukrainy vid 19.01.2023 r. No. 102: 79.

13. Mykolyshyn LI, Piskur ZI, Didyk YY, Sikirynska OS. (2016). Klinichni parametry vitaminu D pry tuberkulozi u ditei. Tuberkuloz, lehenevi khvoroby, VIL-infektsiia. 4 (27): 25-31.

14. Parrinello C, Crossa A, Harris TG. (2012). Seasonality of tuberculosis in New York City, 1990-2007. International J. of Tuberculosis and Lungs diseases. 16: 32-37. https://doi.org/10.5588/ijtld.11.0145; PMid:22236842

15. Petrenko VI ta in. (2017). Profilaktyka tuberkulozu. Navch. posib. Kyiv: TOV «Kyiv. TOV «Ridzhi»: 88.

16. Rekalova OM, Belohortseva OI, Koval NH. (2017). Imunolohichni metody diahnostyky tuberkulozu. Tuberkuloz, lehenevi khvoroby, VIL-infektsiia. 1 (28): 75-83.

17. Sakhelashvili MI, Kostyk OP, Platonova IL ta in. (2017). Aktualni problemy multyrezystentnoho tuberkulozu ta tuberkulozu z rozshyrenoiu rezystentnistiu u Lvivskii oblasti. Ukr. pulmonoloh. zhurnal. 2: 119-120.

18. Wingfield T, Schumacher SG, Sandhu G et al. (2014). The Seasonality of Tuberculosis, Sunlight, Vitamin D, and Household Crowding. J. of Infectious Disease. 210: 774-783. https://doi.org/10.1093/infdis/jiu121; PMid:24596279 PMCid:PMC4130318